

AMSTER
ROTHSTEIN
& EBENSTEIN LLP

Intellectual Property Law

90 Park Avenue
New York NY 10016

Main 212 336 8000

Fax 212 336 8001

Web www.arelaw.com



Partners

Morton Amster
Jesse Rothstein (1934 - 2003)
Daniel Ebenstein
Philip H. Gottfried
Michael J. Berger
Neil M. Zipkin
Anthony F. Lo Cicero
Kenneth P. George
Abraham Kasdan, Ph.D.
Ira E. Silfin
Chester Rothstein
Craig J. Arnold

Kenneth M. Bernstein

Joseph M. Casino
Michael V. Solomita

Senior Counsel

Charles R. Macedo
John S. Economou
Marion P. Metelski

Associates

Patrick Boland*
Holly Pekowsky
Michael P. Kenney

Max Vern

Karl J. Kolbinger
Brian A. Comack
Richard S. Mandaro
Marc J. Jason
Elie H. Gendloff, Ph.D.
David Mitnick
Charles W. Rath
David A. Boag
Matthieu Hausig
Jung S. Hahm
Reiko Kaji
Alan D. Miller, Ph.D.

Norajean McCaffrey

Benjamin M. Halpern*
Matthew A. Fox
Michael J. Kasdan
Jason M. Rockman
Stuart Shapley
Howard Wizenfeld
Steven B. Gauthier

*Not admitted in New York

May 8, 2007

Elie H. Gendloff, Ph.D., Esq.

Direct 212 336 8108

E-mail egendlof@arelaw.com

Via Express Mail

(EV 725834000 US)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

| | |
|---|------------------|
| "Express Mail" mailing label No. | EV 725834000 US |
| Date of Deposit: | May 8, 2007 |
| I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. | |
| Name: | Elie H. Gendloff |
| Signature: | |

Re: U.S. Utility Patent Application No. 10/501,628

Title: MUTATIONS CAUSED BY ACTIVATION-INDUCED
CYTIDINE DEAMINASE

Inventors: Alberto Martin and Matthew D. Scharff

Our File: 96700/905

Dear Sir:

Pursuant to 37 C.F.R. §§§ 1.56, 1.97 and 1.98, enclosed please find the following documents in connection with the above-identified application in the names of Alberto Martin and Matthew D. Scharff, entitled MUTATIONS CAUSED BY ACTIVATION-INDUCED CYTIDINE DEAMINASE, comprising the following:

1. a "Supplemental Information Disclosure Statement," (2 pages);
2. an "Information Disclosure Statement By Applicant" Form PTO/SB/08B (1 page) with three non-patent references cited therein and attached thereto; and
3. a return receipt postcard.

Commissioner for Patents
Alexandria, VA 22313-1450
Mail Stop Amendment
Application Serial No. 10/501,628

-2-


May 8, 2007


Please acknowledge receipt of the enclosed documents by stamping the enclosed postcard and returning same.

Respectfully submitted,

Amster Rothstein & Ebenstein LLP
Attorneys for Applicants
90 Park Avenue
New York, NY 10016
212 336 8000

Dated: New York, New York
May 8, 2007

By: 
Elie Gendloff
Registration No. 44,704



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/501,628

Confirmation No. 2223

Applicants : Alberto Martin and Matthew D. Scharff

Filed : November 22, 2004

Art Unit : 1636

Examiner : Kimberly A. Makar, Ph.D.

Docket No. : 96700/905

Customer No. : 1912

| | |
|---|------------------|
| "Express Mail" mailing label No. | EV 725834000 US |
| Date of Deposit: | May 8, 2007 |
| I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. | |
| Name: | Elie H. Gendloff |
| Signature: | |

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


Pursuant to 37 C.F.R. §§§ 1.56, 1.97, and 1.98, applicants enclose herewith Form PTO/SB/08B, along with the three publications cited therein, representing the second supplemental Information Disclosure Statement submitted in this patent application. Please enter the enclosed supplemental Information Disclosure Statement.


It is believed that no fee is required with this submission. However, if there are any fees required to maintain pendency of this application, authorization is hereby given to charge that fee to Deposit Account No. 01-1785.

Respectfully submitted

AMSTER, ROTHSTEIN & EBENSTEIN LLP
Attorneys for Applicant
90 Park Avenue
New York, NY 10016
(212) 336-8000

Dated: New York, New York
May 8, 2007

By: 
Elie H. Gendloff
Registration No.: 44,704



PTO/SB/08B (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|--------------------------|
| Application Number | 10/501,628 |
| Filing Date | November 22, 2004 |
| First Named Inventor | Alberto Martin |
| Art Unit | 1636 |
| Examiner Name | Kimberly A. Makar, Ph.D. |
| Attorney Docket Number | 96700/905 |

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|-----------------------|--------------------------|---|----------------|
| | 1 | CUMBERS, S.J. et al., "Generation and iterative affinity maturation of antibodies in vitro using hypermutating B-cell lines"; Nature Biotechnology, 2002, Vol. 20, pp1129-34. | |
| | 2 | STORB, U. et al., "Somatic hypermutation of immunoglobulin and non-immuoglobulin genes"; Phil. Trans. R. Soc. Lond. B, 2001, Vol. 356, pp. 13-19 | |
| | 3 | WANG, L. et al., "Evolution of new nonantibody proteins via iterative somatic hypermutation"; PNAS, 2004, Vol. 101, No. 48, pp. 16745-49. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.